Business Context and Reporting Period
Company: Ionis Pharmaceuticals, Inc. (IONS)
Filing Type: Form 8-K (Current Report)
Report Date: July 29, 2026
Reporting Period: Quarter ended June 30, 2026
Context: The filing announces the issuance of a press release containing financial results for the quarter ended June 30, 2026. The report includes both GAAP and non-GAAP (pro forma) results, with the latter excluding non-cash compensation expense related to equity awards and related tax effects to aid in performance assessment.
Key Financial Metrics
The provided text serves as a cover document referencing a press release (Exhibit 99.1) but does not contain the specific numerical data for the following metrics:
- Revenue: Not provided in the filing text.
- Profit/Loss: Not provided in the filing text.
- Cash Flow: Not provided in the filing text.
- Margins: Not provided in the filing text.
- Debt and Liquidity: Not provided in the filing text.
Note: The filing states that the Company discloses pro forma results excluding non-cash compensation, but the specific values are not included in this document.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. It only confirms the announcement of results for the quarter ended June 30, 2026.
Guidance, Outlook, and Risks
Management Commentary: Management states that presenting pro forma information excluding non-cash compensation expense better enables users to assess historical performance and project future operating results and cash flows.
Guidance and Outlook: No specific forward-looking guidance or outlook figures are provided in this text.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated July 29, 2026) for the actual numerical financial results, as they are not embedded in the 8-K text.
- Verify the specific adjustments made to derive the non-GAAP (pro forma) figures, particularly regarding non-cash compensation and tax effects.
- Compare the reported Q2 2026 results against the Q2 2025 period to assess year-over-year trends once the press release data is obtained.
- Confirm the company's liquidity position and cash burn rate from the full financial statements referenced in the press release.